Rohto Pharmaceutical Co., Ltd. (4527) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Rohto Pharmaceutical Co., Ltd. (4527:JPX), powered by AI.

Current Price
¥2,279
P/E Ratio
16.7
Market Cap
519.2B
Sector
Consumer Defensive
What is the Rohto Pharmaceutical Co., Ltd. stock price forecast?

Rohto Pharmaceutical Co., Ltd. is currently trading at ¥2,279. View real-time AI analysis on Alpha Lenz.

What is Rohto Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Rohto Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Rohto Pharmaceutical Co., Ltd.'s P/E ratio?

Rohto Pharmaceutical Co., Ltd.'s P/E ratio is 16.7.

Rohto Pharmaceutical Co., Ltd.

JPX · 4527
¥2,279-45(-1.94%)Market closedJPX regular session 09:00–15:00 JST
Ask about Rohto Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Rohto Pharmaceutical Co., Ltd. trades at a P/E of 16.7 (fair value) with solid ROE of 12.2%. 3Y revenue CAGR of 15.6% highlights clear growth momentum.

Ask for details

Company Overview

Rohto Pharmaceutical Co., Ltd. is a prominent entity in the pharmaceutical industry, specializing in the research, development, and distribution of a diverse range of health and wellness products. Established in Japan, the company has gained recognition for its innovative solutions in skincare, internal health, and general wellness. Rohto's primary function is to cater to the evolving needs of consumers seeking advanced therapeutic options and everyday health maintenance products. The company's extensive product line includes over-the-counter medications, skincare items like acne treatments and anti-aging creams, and eye care solutions such as soothing eye drops. Additionally, Rohto is renowned for its mentholated products, which offer relief for minor aches and nasal congestion. The firm operates not just locally but on a global scale, extending its reach into international markets and contributing significantly to the healthcare sector. Rohto Pharmaceutical Co., Ltd. plays a crucial role in the provision of accessible healthcare solutions, adapting to consumer preferences with continuous research advancements and product enhancements. It holds significant market influence, underpinned by its commitment to enhancing quality of life through innovative and reliable health products.

CEOMr. Yamada Kunio
SectorConsumer Defensive
IndustryHousehold & Personal Products
Employees9,144

Company Statistics

FY 2025

Profile

¥519,158,576,997Market Cap
¥308,625,000,000Revenue
0.00Shares Out
9,144Employees

Margins

56.68%Gross
17.77%EBITDA
12.62%Operating
13.72%Pre-Tax
10.03%Net

Valuation

16.74P/E
2.00P/B
1.68EV/Sales
9.18EV/EBITDA
19.70P/FCF

Growth (CAGR)

15.63%Rev 3Yr
10.38%Rev 5Yr
10.30%Op Inc 3Yr
11.54%Op Inc 5Yr
13.46%Net Inc 3Yr
15.16%Net Inc 5Yr

Returns

8.06%ROA
12.24%ROE
11.27%ROIC

Financial Health

¥77,161,000,000Cash & Cash Equivalents
¥73,276,000,000Net Debt
55.42%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Rohto Pharmaceutical Co., Ltd. (ticker: 4527) is a company listed on JPX in the Consumer Defensive sector (Household & Personal Products). It has approximately 9,144 employees. Market cap is $519.2B.

The current price is 2,279 with a P/E ratio of 16.74x and P/B of 2x.

ROE is 12.24% and operating margin is 12.62%. Annual revenue is $308.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Rohto Pharmaceutical Co., Ltd. (4527) Stock Forecast 2026 ¥2,279 — Price, Financials & Analyst Targets | Alpha Lenz